Pfizer to relaunch Corex in new formulation

Hyderabad: Pfizer Ltd, Indian subsidiary of US-based drug maker Pfizer Inc., on Tuesday said it has decided to discontinue its popular cough syrup Corex in the present form, though it will retain the brand name for its future respiratory products. The company said it has decided to stop making the current Corex cough syrup formulation which is a combination of codeine phosphate 10 mg and chlorpheniramine maleate 4mg. “Pfizer stands by the safety and efficacy of its current Corex cough syrup formulation that has been duly approved by central and state regulators. The company remains committed to providing a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current Corex cough syrup formulation.